Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Easy there George Jefferson! ;)
Or, it's nothing....
Ummm, really odd. Haven't seen this since we went to 16...
Why do you say that?
Yep, that is a bit frustrating, to say the least.
Probably so but we all want to see this thing pop! Once and for all! Too many false starts. :)
Stone, if you can decipher pre-market you're a genius. Wait, you are a genius, sorry. ;) I've seen way too many pops up in pre-market that fade away at the start. Good luck, my friend.
Yeah, the delivery system was flawed or something? That was in the dark ages...Cheers.
We never had a PH.III have we? Just trying to remember when we had fast track before...peace.
Did we get fast track once before??? Cotara??? GLTA
Never thought I'd see it. A Phase III starts. GLTA. TerryGD is smiling somewhere.....
Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer
Company Launches www.SunriseTrial.com to Assist Patients and Physicians
TUSTIN, CA -- (Marketwired) -- 12/30/13 -- Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), today announced the opening to enrollment of its SUNRISE trial at leading oncology centers in the United States. SUNRISE is a pivotal Phase III clinical trial comparing the company's investigational immunotherapy bavituximab plus the chemotherapy docetaxel against placebo plus the chemotherapy docetaxel in patients with second-line non-small cell lung cancer (NSCLC). This trial will enroll approximately 600patients from more than 100 medical centers worldwide.
"The design of the SUNRISE trial was based on the compelling Phase II data demonstrating encouraging improvement in overall survival in patients with second-line NSCLC. Furthermore, peer-reviewed published data support that bavituximab and docetaxel share highly compatible mechanisms of action that we believe hold promise for improved patient outcomes,"1-6 said Joe Shan, MPH, vice president of clinical and regulatory affairs at Peregrine. "We believe harnessing the body's natural immune system to fight cancer will be an integral part to conquering this deadly disease. Multiple peer-reviewed published data support bavituximab's immunotherapy mechanism of action whereby the targeted monoclonal antibody blocks an immune checkpoint responsible for immune suppression at the local tumor environment, thereby allowing the immune system to recognize and fight this deadly disease."
"This is a significant milestone for the company as patients with advanced non-small cell lung cancer who have progressed on a prior treatment have few therapeutic options, and new approaches to managing their disease are in demand," said Steven King, chief executive officer of Peregrine. "As part of our plan to provide patient and physicians with the necessary information regarding this trial, today we launched the SunriseTrial.com web portal to serve as a gateway for trial parameters and additional resources. We anticipate that in executing our global plan we can enroll the majority of patients in this trial from the United States and Western Europe."
SUNRISE ("Stimulating ImmUne RespoNse thRough BavItuximab in a PhaSE III Lung Cancer Study") is a Phase III, global, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the safety, tolerability and efficacy of bavituximab plus docetaxel in patients with second-line NSCLC. The trial will evaluate bavituximab plus docetaxel versus docetaxel plus placebo in approximately 600 patientsat clinical sites worldwide. Patients with Stage IIIb/IV non-squamous, NSCLC who have progressed after standard front-line treatment are eligible for enrollment. Patients will be randomized into 1 of 2 treatment arms. All patients will receive up to six 21-day cycles of docetaxel (75 mg/m2) plus weekly infusions of either bavituximab (3mg/kg) or placebo until progression of toxicity. The primary endpoint of the trial will be overall survival. For additional information about the SUNRISE trial please visit www.SunriseTrial.com or ClinicalTrials.gov using Identifier NCT01999673.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab while seeking a partner to further advance its novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Drip drip drip down again...it never ends...
Yeah, the bottom fell out. Head fake?
Hmmm, up large in pre-market...what the...GLTA
OK, so how big a "bounce"? Let's not get ahead of ourselves. It's happened before and the bounce was minimal. GLTA
Stone, we are ALWAYS looking for good signs. I've learned not to put any importance in pre-market, unless there is solid news behind it. Let's go PPHM, make some noise!
You go biopharm. Connect those dots. GLTA
Loof, I have 5 more years til I hit 20 in PPHM...fingers crossed.
Sure, why not. A million and 1! 15 years and counting....
Looked like a double top with a teacup and saucer chart! Anyone back me up on that....if I knew what the hell that was.
PPHM going for a little jog?
Ummm, OK then. Good luck to all.
Wish you and PPHM nothing but luck. Have a nice weekend.
Sorry, I don't see that happening.
Great response today, huh? Jeeeeeeeezzzzzzzzzzzeeeeeeeeeeeee.
""Peregrine Pharmaceuticals (NASDAQ: PPHM ) is an upstart biotech targeting the treatment and diagnosis of cancer through monoclonal antibodies. It has a potential winner in its lead candidate that will begin its telltale phase 3 clinical trial later this year.""
Upstart? Hardly.
IS PHIII even gonna happen??? oy
I had that dream in 2000! Crashed down....
Wow, I didn't know Thorpe passed away. We lost a great fighter for cancer research. Dang.
"I hope to have a better feeling after the CC and hear their voices."
That never goes well either.
Geo, they just can't keep taking these hits and come back...it's not good.
Stick a fork in us. How many lives do we have at this point? Bad.
YES, I have all the answers!!! haha Enjoy the summer.
No, I post so infrequently, I just like to liven it up once in awhile. peace Go PPHM! How's that?
We been slept for a long time now...WAKE UP!
http://www.nasdaq.com/symbol/pphm/premarket
We are flying! Run Forrest, run! This is it...maybe not.
Peregrine Pharmaceuticals to Join Russell 3000 and Russell Global Indexes
TUSTIN, CA -- (Marketwired) -- 06/24/13 -- Peregrine Pharmaceuticals (NASDAQ: PPHM) today announced that it has received notification it will join the Russell 3000® and Russell Global Indexes when Russell Investments reconstitutes its family of U.S. indexes on June 28, 2013, according to a list of additions posted on June 21, 2013.
The Russell Indexes capture the 4,000 largest U.S. stocks as of the end of May, ranking them by total market capitalization. Russell indexes are reconstituted annually and are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Approximately $4.1 trillion in assets are benchmarked to the Russell Indexes.
Membership in the Russell 3000®, which remains in place for one year, means automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index, as well as the appropriate growth and value style indexes. The Russell 3000 also serves as the U.S. component to the Russell Global Index. Membership in the Russell Global Index, which remains in place for one year, means automatic inclusion in the appropriate large-cap, small-cap, all-cap indexes as well as the applicable style, sector and country indexes. Russell determines membership for its equity indexes primarily by objective, market capitalization rankings and style attributes.
More information on the Russell Indexes, including total returns, is available at http://www.russell.com/Indexes/data/default.asp.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials focused on the treatment and diagnosis of cancer. The company is pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. Additional information about Peregrine can be found at www.peregrineinc.com.
Contact:
Christopher Keenan or Jay Carlson
Peregrine Pharmaceuticals, Inc.
(800) 987-8256
info@peregrineinc.com
Source: Peregrine Pharmaceuticals
Wook, no future here for awhile. Phightins back to .500. Domonic Brown crushing it!
Saw that...could we be the flavor of the month now?????